Domainex and a research team at the Institute of Cancer Research (ICR) have announced a new development in their collaboration to find a new treatment for breast cancer.
The company is now set to provide lead optimisation services alongside the work being undertaken at the ICR.
Scientists led by the ICR's Prof Alan Ashworth of the Breakthrough Breast Cancer Research Centre, working in collaboration with Domainex, have discovered drug-like compounds that inhibit an enzyme from the PARP superfamily, whose expression leads to the survival of breast cancer cells.
Domainex will apply its Leadbuilder virtual screening technology to design and select chemical compounds suitable for rapid progression.
Furthermore, the company will apply its medicinal chemistry expertise to assist the ICR team to develop drug candidates for progression into clinical trials.
